Posted by Michael Wonder on 26 Apr 2021
European Commission approves GSK’s Jemperli (dostarlimab), the first anti-PD-1 therapy approved for recurrent or advanced endometrial cancer
23 April 2021 - The approval makes dostarlimab the first anti-PD-1 therapy available for endometrial cancer in Europe.
GlaxoSmithKline today announced the European Commission has granted conditional marketing authorisation for Jemperli (dostarlimab), a programmed death receptor-1 blocking antibody, for use in women with mismatch repair-deficient/microsatellite instability-high recurrent or advanced endometrial cancer who have progressed on or following prior treatment with a platinum containing regimen.
